Expanded Access Policy
CUTX-101 is under investigation for the treatment of Menkes disease and related copper metabolism disorders. It has not yet been established as safe and effective for any such treatment. Cyprium Therapeutics believes that CUTX-101 should be available and studied in patients as part of an Intermediate-Size Patient Population Expanded Access Protocol to obtain further data on the safety and efficacy of CUTX-101 that may be used to support approval of the product and subsequent wider accessibility to Menkes disease patients. We encourage parents/legal guardians who have children with Menkes disease to speak with their physicians and to consider having their child participate in clinical trials. For more information on criteria and requesting access, please visit this link.
Recent Press Releases
March 2022 :: Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting
December 2021 :: Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
October 2021 :: Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
February 2021 :: Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease